The decline of the incidence of meningococcal disease in Barcelona between 1988 and 2015: the influence of the vaccine against serogroup C
Med Clin (Barc). 2018 Nov 21;151(10):390-396.
doi: 10.1016/j.medcli.2018.01.015.
Epub 2018 Mar 2.
[Article in
English,
Spanish]
Authors
Sandra Manzanares-Laya
1
, Oleguer Parés-Badell
2
, Pilar Gorrindo
3
, Pere Simón
3
, Miriam Ros
3
, Anna de Andrés
3
, Núria López Segura
4
, Sonia Brió Sanagustín
5
, Anna Vilella
6
, Carlos Rodrigo Gonzalo de Liria
7
, Àngels Orcau
8
, Joan A Caylà
8
Affiliations
- 1 Servicio de Epidemiología, Agencia de Salud Pública de Barcelona, Barcelona, España; CIBER Epidemiología y Salud Pública (CIBERESP), España. Electronic address: smanzana@aspb.cat.
- 2 Servicio de Epidemiología, Agencia de Salud Pública de Barcelona, Barcelona, España; Unidad Docente de Medicina Preventiva y Salud Pública, Hospital del Mar, UPF-ASPB, Barcelona, España.
- 3 Servicio de Epidemiología, Agencia de Salud Pública de Barcelona, Barcelona, España.
- 4 Servicio de Pediatría, Hospital del Mar, Barcelona, España.
- 5 Unidad de Cuidados Intensivos Pediátricos, Hospital de Sant Pau, Barcelona, España.
- 6 Servicio de Medicina Preventiva, Hospital Clínico Universitario de Barcelona, Barcelona, España.
- 7 Servicio de Pediatría, Hospital Universitario Vall d'Hebrón, , Barcelona, España.
- 8 Servicio de Epidemiología, Agencia de Salud Pública de Barcelona, Barcelona, España; CIBER Epidemiología y Salud Pública (CIBERESP), España.
Abstract
Introduction and objective:
The purpose of this study was to describe the evolution of meningococcal disease (MD) in the city of Barcelona between 1988 and 2015 and to assess the impact of the vaccine against serogroup C.
Materials and methodology:
The evolution of MD and by serogroup was analysed using the information included in the mandatory notification diseases registry. Incidences of all serogroups between the periods of before and after the implementation of the serogroup C vaccine in 2000 were compared. Vaccination coverage among cases, serogroup among vaccinated cases and mortality and case fatality rates were analysed.
Results:
MD has evolved from an incidence rate in children aged under 1 of 63.09 cases per 100,000 in 1997-2000 to 15.44 per 100,000 in 2001-2015. All MD serogroups incidences decreased after the implementation of the vaccine, especially for serogroup C among children aged between 1 and 4. Since 2000 vaccine coverage in MD cases by this serogroup was 7.6% while in those affected by serogroup B it was 35.0% (p<.01). Among those vaccinated, 66.4% of cases were serogroup B and 5.2% were C (p<.01). Mortality and case fatality rates were 7.7% and 0.19/100,000 respectively, without significant changes in time regarding case fatality.
Conclusions:
Incidence caused by serogroups B and C has decreased after the systematic vaccination against serogroup C. Vaccination against serogroup B could further reduce the impact of this lethal disease which has not decreased during this period.
Keywords:
Disease notification; Incidence; Incidencia; Meningitis meningococcal; Meningitis meningocócica; Mortalidad; Mortality; Notificación de enfermedad; Vaccination; Vacunación.
Copyright © 2018 Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Adolescent
-
Adult
-
Age Distribution
-
Aged
-
Child
-
Child, Preschool
-
Cities / epidemiology
-
Female
-
Humans
-
Incidence
-
Infant
-
Infant, Newborn
-
Male
-
Meningococcal Infections / epidemiology*
-
Meningococcal Infections / mortality
-
Meningococcal Vaccines / administration & dosage*
-
Middle Aged
-
Neisseria meningitidis, Serogroup B / isolation & purification
-
Neisseria meningitidis, Serogroup C* / isolation & purification
-
Retrospective Studies
-
Spain / epidemiology
-
Vaccination
-
Young Adult
Substances
-
Meningococcal Vaccines
-
serogroup C meningococcal conjugate vaccine